Table I.
Demographic characteristics of the study subjects (N = 20).
Clopivas®∗ |
Plavix®† |
|||||
---|---|---|---|---|---|---|
Subject No. | Age, y | Height, cm | BodyWeight, kg | Age, y | Height, cm | BodyWeight, kg |
1 | 28 | 171 | 68 | 30 | 166 | 70 |
2 | 25 | 168 | 62 | 23 | 170 | 72 |
3 | 28 | 168 | 50 | 23 | 175 | 64 |
4 | 29 | 154 | 59 | 21 | 159 | 60 |
5 | 30 | 154 | 50 | 32 | 165 | 60 |
6 | 25 | 156 | 60 | 23 | 164 | 53 |
7 | 23 | 158 | 57 | 26 | 161 | 52 |
8 | 25 | 153 | 50 | 25 | 172 | 53 |
9 | 22 | 165 | 53 | 31 | 158 | 66 |
10 | 30 | 156 | 53 | 22 | 166 | 65 |
Mean | 26.5 | 160.3 | 56.2 | 25.6 | 165.6 | 61.5 |
SD | 2.9 | 6.9 | 6.1 | 4.0 | 5.5 | 7.2 |
Trademark of Cipla Ltd (Mumbai, India).
Trademark of Sanofi Pharma (Paris, France) and Bristol-Myers Squibb Company (Wallingford, Connecticut).